HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graham, G. D. Articles by Prichard, J. W. Search for Related Content PubMed PubMed Citation Articles by Graham, G. D. Articles by Prichard, J. W.

Proton magnetic resonance spectroscopy in Creutzfeldt-Jakob disease

From the Departments of Neurology (Drs. Graham, Petroff, and Prichard), Molecular Biophysics and Biochemistry (Dr. Blamire), and Neurobiology (Drs. Rajkowska and Goldman-Rakic), Yale University School of Medicine, New Haven, CT.

We studied two patients with Creutzfeldt-Jakob disease by in vivo proton magnetic resonance spectroscopy and obtained spectra from an extract of biopsy tissue from a third patient. In vivo spectra from the two patients, 3 months and less than 1 month after symptom onset, revealed only minor changes. A second study of one of the patients 10 months after symptom onset found a decrease in N-acetylaspartate and other metabolites. Spectroscopy of the biopsy extract obtained 4 months after onset of symptoms showed no reduction in metabolites measured by in vivo spectroscopy, in accord with quantitative pathology showing no overall neuronal loss. Changes in metabolites detectable by proton magnetic resonance spectroscopy are not an early feature of this disease.

Address correspondence and reprint requests to Dr. Glenn D. Graham, Department of Neurology, LCI 7, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510.

Presented at the 44th annual meeting of the American Academy of Neurology, San Diego, CA, May 1992.

Supported by National Institutes of Health grants NS21708 and NS27883.

Received September 30, 1992. Accepted for publication in final form February 10, 1993.

This article has been cited by other articles:

				R. Lodi, P. Parchi, C. Tonon, D. Manners, S. Capellari, R. Strammiello, R. Rinaldi, C. Testa, E. Malucelli, B. Mostacci, et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study Brain, October 1, 2009; 132(10): 2669 - 2679. [Abstract] [Full Text] [PDF]

				R G Macfarlane, S J Wroe, J Collinge, T A Yousry, and H R Jager Neuroimaging findings in human prion disease J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 664 - 670. [Abstract] [Full Text] [PDF]

				C Oppenheim, M Zuber, D Galanaud, M Detilleux, F Bolgert, J L Mas, J Chiras, and J F Meder Spectroscopy and serial diffusion MR findings in hGH-Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 1066 - 1069. [Abstract] [Full Text] [PDF]

				K. H. Taber, P. Cortelli, W. Staffen, and R. A. Hurley The Expanding Role of Imaging in Prion Disease J Neuropsychiatry Clin Neurosci, November 1, 2002; 14(4): 371 - 376. [Full Text] [PDF]

				Y. Mao-Draayer, S. P. Braff, K. J. Nagle, W. Pendlebury, P. L. Penar, and R. E. Shapiro Emerging Patterns of Diffusion-Weighted MR Imaging in Creutzfeldt-Jakob Disease: Case Report and Review of the Literature AJNR Am. J. Neuroradiol., April 1, 2002; 23(4): 550 - 556. [Abstract] [Full Text] [PDF]

				A. A. Rabinstein, M. L. Whiteman, and R. T. Shebert Abnormal Diffusion-Weighted Magnetic Resonance Imaging in Creutzfeldt-Jakob Disease Following Corneal Transplantations Arch Neurol, April 1, 2002; 59(4): 637 - 639. [Abstract] [Full Text] [PDF]

				M. M. Bahn and P. Parchi Abnormal Diffusion-Weighted Magnetic Resonance Images in Creutzfeldt-Jakob Disease Arch Neurol, May 1, 1999; 56(5): 577 - 583. [Abstract] [Full Text] [PDF]